We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

20 hedge funds and large institutions have $2.6M invested in vTv Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0% less ownership

Funds ownership: 0.11% → 0.11% (-0%)

10% less capital invested

Capital invested by funds: $2.88M → $2.6M (-$276K)

17% less funds holding

Funds holding: 24 → 20 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
20
Holders Change
-4
Holders Change %
-16.67%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$48.4K
2
Northern Trust
Northern Trust
Illinois
+$7.82K
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.07K
4
BlackRock
BlackRock
New York
+$32

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$35K
2
VF
Virtu Financial
New York
-$27K
3
BCM
Bridgeway Capital Management
Texas
-$21.8K
4
Citadel Advisors
Citadel Advisors
Florida
-$19.6K
5
UBS Group
UBS Group
Switzerland
-$775
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$1.21M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$695K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$214K – – –
V
4
Veritable
Delaware
$180K – – –
State Street
5
State Street
Massachusetts
$99.7K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$56.4K +$48.4K +1,524 +399%
BlackRock
7
BlackRock
New York
$40.8K +$32 +1 +0.1%
Northern Trust
8
Northern Trust
Illinois
$37.3K +$7.82K +246 +24%
Morgan Stanley
9
Morgan Stanley
New York
$24.7K – – –
SQA
10
Simon Quick Advisors
New Jersey
$22.2K – – –
FWM
11
Focused Wealth Management
New York
$7.4K – – –
SFCL
12
Strengthening Families & Communities LLC
Massachusetts
$5K -$223 -7 -4%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$3.83K +$4.07K +128 +6,400%
Osaic Holdings
14
Osaic Holdings
Arizona
$1.52K – – –
PA
15
Parallel Advisors
California
$1.11K – – –
Wells Fargo
16
Wells Fargo
California
$909 – – –
CPG
17
Cornerstone Planning Group
New Jersey
$555 +$604 +19 New
SS
18
Sunbelt Securities
Texas
$444 – – –
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
$243 – – –
Millennium Management
20
Millennium Management
New York
– -$35K -1,095 Closed
VF
21
Virtu Financial
New York
– -$27K -832 Closed
BCM
22
Bridgeway Capital Management
Texas
– -$21.8K -675 Closed
Citadel Advisors
23
Citadel Advisors
Florida
– -$19.6K -606 Closed
UBS Group
24
UBS Group
Switzerland
– -$775 -24 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$286 -9 -75%

VTVT Hedge Fund Activity: Q2 2023 in Review

20 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2023, worth a combined $2.6M — down 9.6% from $2.88M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of VTVT and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Susquehanna International Group, adding an estimated $48.4K. The largest seller was Millennium Management, exiting entirely with an estimated $35K sold.

  • 20 institutional investors held vTv Therapeutics (VTVT) as of Q2 2023, down from 24 in Q1 2023.
  • Funds reported $2.6M of vTv Therapeutics stock for Q2 2023, down 9.6% quarter-over-quarter.
  • 1 fund opened new vTv Therapeutics positions in Q2 2023 and 5 closed out, a net change of -4 holders.
  • The largest vTv Therapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $48.4K added.
  • The largest vTv Therapeutics seller in Q2 2023 was Millennium Management, an estimated $35K sold.

Based on aggregated 13F filings for Q2 2023.